Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
PYC Therapeutics Limited (PYC.AX)
Nedlands, WA, AU
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.88% | -0.74% | +7.14% | -10.60% | -15.63% | -18.67% | +12.50% | +143.39% | -19.64% | +884.32% | -36.02% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 4 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+6.5% ★ Q4'25: -100.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-941.7% Q4'25: -855.0% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-139.4%
-
EBIT margin Biotechnology: +0.0%-228.3%
-
ROIC Biotechnology: -16.1%-298.2% Q4'25: -348.1% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-87.3% ★ Q4'25: -84.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q4'25: -0.01× (vs Q4'23)
| Metric |
Jun 2023 actual |
Jun 2024 actual |
Jun 2025 actual |
Jun 2026 1 Rev. Ana. 4 EPS Ana. |
Jun 2027 2 Rev. Ana. 5 EPS Ana. |
Jun 2028 3 Rev. Ana. 5 EPS Ana. |
Jun 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
15.81M
est: 8.00M (+97.6%)
|
22.06M
est: 6.28M (+251.5%)
|
23.49M
est: 11.67M (+101.4%)
|
5.00M
5.00M – 5.00M
-57.1% YoY
|
5.00M
5.00M – 5.00M
+0.0% YoY
|
102.67M
102.67M – 102.67M
+1,953.3% YoY
|
230.77M
230.77M – 230.77M
+124.8% YoY
|
| EBITDA |
-38.25M
est: -8.00M (-378.2%)
|
-54.55M
est: -6.28M (-769.4%)
|
-52.88M
est: -11.67M (-353.2%)
|
-5.00M
-5.00M – -5.00M
+57.1% YoY
|
-5.00M
-5.00M – -5.00M
+0.0% YoY
|
-102.67M
-102.67M – -102.67M
-1,953.3% YoY
|
-230.77M
-230.77M – -230.77M
-124.8% YoY
|
| EBIT |
-39.14M
est: -8.00M (-389.2%)
|
-55.62M
est: -6.28M (-786.4%)
|
-53.63M
est: -11.67M (-359.7%)
|
-5.00M
-5.00M – -5.00M
+57.1% YoY
|
-5.00M
-5.00M – -5.00M
+0.0% YoY
|
-102.67M
-102.67M – -102.67M
-1,953.3% YoY
|
-230.77M
-230.77M – -230.77M
-124.8% YoY
|
| Net Income |
-22.79M
est: -39.85M (+42.8%)
|
-37.73M
est: -39.19M (+3.7%)
|
-50.30M
est: -50.30M (+0.0%)
|
-38.29M
-50.05M – -26.53M
+23.9% YoY
|
-50.90M
-58.94M – -42.86M
-32.9% YoY
|
-87.28M
-98.46M – 54.10M
-71.5% YoY
|
39.37M
39.37M – 39.37M
+145.1% YoY
|
| SGA |
3.14M
est: 5.41M (-42.0%)
|
4.51M
est: 4.24M (+6.3%)
|
7.07M
est: 7.89M (-10.4%)
|
3.38M
3.38M – 3.38M
-57.1% YoY
|
3.38M
3.38M – 3.38M
+0.0% YoY
|
69.41M
69.41M – 69.41M
+1,953.3% YoY
|
156.02M
156.02M – 156.02M
+124.8% YoY
|
| EPS |
-0.01
est: -0.08 (+91.2%)
|
-0.01
est: -0.08 (+87.7%)
|
-0.10
est: -0.09 (-9.5%)
|
-0.07
-0.10 – -0.05
+18.7% YoY
|
-0.10
-0.12 – -0.09
-37.7% YoY
|
-0.08
-0.20 – 0.11
+17.6% YoY
|
0.08
0.08 – 0.08
+193.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard MSCI Australian Small Companies Index ETF VSO.AX | 0.13% | 1.05M | 0.30% |
| 2 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.02% | 35.0K | 0.83% |
| 3 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.02% | 2.11M | 0.40% |
| 4 | iShares Core MSCI Pacific ETF IPAC | 0.01% | 147.0K | 0.09% |
| 5 | State Street SPDR MSCI World Small Cap UCITS ETF (Acc) WDSC.L | 0.00% | 59.4K | 0.45% |
| 6 | Dimensional - International Small Cap ETF DFIS | 0.00% | 60.9K | 0.39% |
| 7 | iShares Morningstar Multi-Asset Income ETF IYLD | 0.00% | 642.54 | 0.50% |
| 8 | iShares Core MSCI EAFE IMI Index ETF (CAD-Hedged) XFH.TO | 0.00% | 8.1K | 0.23% |
| 9 | iShares Core MSCI EAFE IMI Index ETF XEF.TO | 0.00% | 57.9K | 0.23% |
| 10 | iShares Core MSCI EAFE ETF IEFA | 0.00% | 359.0K | 0.07% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rohan Hockings MBBS MBBS | Chief Executive Officer & Executive Director | 625.5K | — |
| Kevin Ronald Hart | Company Secretary | 165.9K | male |
| Janya Grainok | Chief Discovery Officer | — | — |
| Paula Cunningham | Chief Pre-Clinical Research Officer | — | — |
| Sean Houthuysen | General Counsel | — | male |
| Daniel Coletta | Joint Company Secretary | — | male |
| Sri Mudumba | Chief Research & Development Officer | — | — |
| Garrett Bray | Chief Operating Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PYC.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
